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Fred R Hirsch, Giorgio V Scagliotti, James L Mulshine, Regina Kwon, Walter J Curran, Yi-Long Wu, Luis Paz-Ares
Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed 
with lung cancer, and 1·6 million people die as a result of the disease. 5-year survival rates vary from 4–17% depending 
on stage and regional diff erences. In this Seminar, we discuss existing treatment for patients with lung cancer and the 
promise of precision medicine, with special emphasis on new targeted therapies. Some subgroups, eg—patients with 
poor performance status and elderly patients—are not specifi cally addressed, because these groups require special 
treatment considerations and no frameworks have been established in terms of new targeted therapies. We discuss 
prevention and early detection of lung cancer with an emphasis on lung cancer screening. Although we acknowledge the 
importance of smoking prevention and cessation, this is a large topic beyond the scope of this Seminar.
Introduction
Every year, 1·8 million people are diagnosed with lung 
cancer and 1·6 million die of the disease.1 5-year survival in 
populations with lung cancer varies from 4–17% depending 
on stage and regional diff erences.2 Much progress has been 
made in research, lung cancer screening, and personalised 
therapy (precision medicine) in recent years.
Early lung cancer detection using spiral CT
The National Lung Screening Trial (NLST)3 enrolled 
53 000 individuals aged 55–74 years with a 30-pack-year 
smoking history. Participants were randomly assigned to 
radiography or low-dose CT and screened at baseline with 
two annual follow-up scans. Maximum follow-up lasted 
for 7 years. The low-dose CT group had a 20% reduction 
in lung cancer mortality and a 6·7% reduction in all-cause 
mortality.3 The high rates of false-positive fi ndings (27% at 
baseline, 28% at 1-year follow-up, 16·6% at 2-year 
follow-up) were concerning (table 1).3
The International Early Lung Cancer Action Program 
retrospectively analysed the outcomes of more than 
21 000 prospectively enrolled patients who underwent 
lung cancer screening after the completion of the NLST.6 
Diff erent size thresholds for nodule diameter resulted in 
diff erent cancer diagnosis rates. Increasing the threshold 
from 5·0 mm to 6·0, 7·0, 8·0, or 9·0 mm also changed 
the frequencies of positive results. Depending on where 
the size threshold was reset from 5·0 mm, the diagnostic 
work-up frequency could be reduced by 36% for 6·0 mm, 
56% for 7·0 mm, 68% for 8·0 mm, or 75% for 9·0 mm. 
With annual screening, the resultant delay in eventual 
diagnosis was not associated with a reduction in curative-
intent surgery.6 
In NELSON,4 a Dutch and Belgian randomised screening 
trial, a two-part criterion for potential cancer was tested 
using analysis of the diameter change of a nodule. Of the 
7155 prospective participants in the CT screening group, 
the sensitivity of CT screening was 92·4% and the 
specifi city was 90·0%, which suggests that effi  cient case 
detection was feasible. In the UK Lung Cancer Screening 
Trial,5 for the 2028 patients randomly assigned to CT 
screening, 536 patients had nodules greater than 5 mm in 
diameter, and 41 of the 536 patients had lung cancer. The 
false-positive rate was reported to be 3·6%.5
The American College of Radiology (ACR) proposed 
Lung-RADS, a classifi cation system similar to the system 
that the ACR use for breast cancer screening, in order to 
standardise the routine clinical management of lung 
cancer detection.7 When this approach was retrospectively 
applied to the NLST data, they revealed a proportion of 
false-positive results at baseline of 12·8%, in contrast to 
26·6% reported by the NLST.8 The corresponding false-
positive proportion after baseline was 5·5% for Lung-
RADS, versus 21·8% for NLST.8 These eff orts suggest 
lung cancer screening management can be delivered 
with greater effi  ciency than the approach used 10 years 
ago in the NLST.3
Other changing aspects of CT screening include the 
use of lower medical radiation doses for imaging.9 
Updates to the international lung cancer pathology 
classifi cation have improved delineation of the types of 
lung processes associated with invasive versus benign 
clinical behaviour.10 A review11 of the outcomes of 
57 496 international screening cases substantiated the 
indolent behaviour of non-solid pulmonary nodules, and 
suggests that, in this setting, a more conservative 
approach to surgical resection is appropriate. This 
fi nding complements a number of reports about better 
management of screen-detected lung cancer and 
reducing the potential for surgical overtreatment.12,13
The UK Lung Cancer Screening Trial5 reported the 
cost-eff ectiveness of one-time screening was £8466 per 
quality-adjusted life-year. This is similar to the robust 
actuarial cost projection for lung cancer screening in the 
USA.14 Inclusion of best-practice tobacco cessation 
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Search strategy and selection criteria
We did our primary search from Nov 1, 2015, to 
Jan 31, 2016, with continuous monitoring of the literature 
until June 30, 2016. Searches were done in PubMed in 
English using the phrase “lung cancer” in combination with 
“early stage”, “advanced stage”, “targeted therapy”, and 
“immunotherapy”. Relevant studies were chosen based on 
the expertise of the co-authors. Additional reports were 
taken from international conferences in the USA, Europe, 
and Asia. 
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services in the screening process reduces the overall 
health-care cost by about a third.14 However, a 2015 survey15 
of US screening centres suggested that only 36·6% of 
these sites were prepared to provide optimal intensity 
tobacco cessation services.
Under the provisions of the Aff ordable Care Act, public 
and private insurers in the USA are required to cover the 
cost of recommended cancer screening services without 
cost to the consumer.12 As evidence for screening 
increases and favourable cost data emerge, international 
interest in this new service is spreading, as refl ected by 
reports outlining national lung cancer screening 
guidelines for China and Canada.16,17 Biomarker testing is 
also an area of intense ongoing interest. However, further 
research into improving screening effi  ciency is key to 
optimisation of its potentially great but fragile benefi t.18 
To reduce fi nancial stress on health-care systems, 
screening should be delivered with integrated tobacco 
cessation.
Treatment of early-stage lung cancer
Surgery is the recommended treatment for patients with 
stage I–II non-small-cell lung cancer (NSCLC).19 5-year 
survival is 77–92% for clinical stage IA, 68% for stage IB, 
60% for stage IIA, and 53% for stage IIB. By pathological 
stage, 5-year survival is 80–90% for stage IA, 73% for 
stage IB, 65% for stage IIA, and 56% for stage IIB.20 
Results of large meta-analyses21 have shown that 
video-assisted techniques give better quality of life and 
long-term outcomes compared with open lobectomy, and 
studies in stage I disease show equal or better survival 
after video-assisted techniques. The role of perioperative 
chemotherapy has been addressed in many randomised 
studies,22 and a meta-analysis23 found a survival benefi t 
for patients with stage IB–IIIA disease, with a reduced 
hazard ratio (HR) of 0·83–0·92 and absolute survival 
benefi ts of 5·4–6·9% at 5 years. In a pooled analysis by 
the Lung Adjuvant Cisplatin Evaluation collaborative 
group,22 the 5-year survival for the control group was 
87·7% (including all-cause mortality). The role of targeted 
therapies in this setting is not defi ned.24,25 Results of a 
large randomised trial (ECOG 1505) showed no benefi t to 
using adjuvant bevacizumab in unselected early stage 
patients.26 Results from the large prospective placebo-
controlled RADIANT study24 showed no benefi t from the 
use of adjuvant epidermal growth factor receptor tyrosine 
kinase inhibitor (EGFR TKI) erlotinib; however, the study 
was not designed specifi cally for patients with tumours 
harbouring EGFR mutations.24 Results of other studies 
have shown no eff ect of EGFR TKIs as adjuvant therapy 
in unselected patients.25 Ongoing large prospective 
studies (eg, the ALCHEMIST screening trial, 
NCT02194738) and other studies are investigating the 
role of EGFR TKIs in the EGFR-mutant population, 
ALK inhibitors in the ALK-positive population, 
and immunotherapy in the non-biomarker-selected 
population.27,28
For patients with clinical stage I NSCLC who have 
medical contraindications to surgical resection or who 
refuse surgery, high-dose stereotactic body radiation 
therapy resulted in high local tumour control and low 
toxicity. Although there are no randomised data 
comparing stereotactic body radiation to other non-
operative fi rst-line approaches such as radiofrequency 
ablation, standard radiotherapy, and chemotherapy, 
several phase 2 trials cite local tumour-control rates of 
more than 85% at 5 years.29,30 Stereotactic body radiation 
uses highly sophisticated planning and delivery 
technology, and the most common regimen delivers 
three fractions of 18·0 Gy, each to the target volume.
For patients with locally advanced NSCLC 
(stages IIIA–B) not amenable to surgical resection, and 
with good performance status, the current standard of 
care involves a 6-week course of thoracic radiotherapy 
with the concurrent delivery of doublet chemotherapy 
using either cisplatin or carboplatin and a second drug 
per week or every 3 weeks.31,32 The recommended total 
radiotherapy dose is 60–66 Gy, and best practice includes 
CT-based planning and the use of either three-
dimensional planning and delivery or intensity 
modulated radiation therapy.33 No targeted agent has yet 
been established as eff ective in conjunction with this 
chemotherapy and radiotherapy regimen. Multicentre 
trials have reported median survival times in excess of 
2 years, and 5-year survival of 15–20%.33,34
Treatment of advanced lung cancer
Therapeutic progress for subgroups of NSCLC can 
largely be attributed to the accumulation of molecular 
knowledge through emerging technology platforms (eg, 
next-generation sequencing and other omics platforms) 
and the development of new drugs that specifi cally target 
molecular abnormalities (appendix). Patients who have 
neoplasms with specifi c genomic aberrations have 
benefi ted from molecular targeted therapies (table 2). Up 
to 69% of patients with advanced NSCLC could have a 
potentially actionable molecular target (fi gure, table 3).35 
Stage I 
(%)*
Round 1 Round 2
Total 
patients 
screened 
(n)
Cancer 
diagnoses 
(n)
Proportion 
of patients 
diagnosed 
with cancer 
(%)
Total patients 
screened (n)
Cancer 
diagnoses 
(n)
Proportion 
of patients 
diagnosed 
with cancer 
(%)
National Lung 
Screening Trial3
66 24 715 168 0·67 24 102 211 0·87
NELSON4 73·7 7289 40 0·5 7289 57 0·8
UK Lung Cancer 
Screening Trial5
66·7 2028 34 1·7 2028 8 0·4
*Proportion of detected cancers that were stage I. Results are from the fi rst year of screening, except for NELSON, 
in which round 2 and 3 screening data are presented together, refl ecting the study design. 
Table 1: Cancer detection and frequency of stage I cancer detection in clinical trials
See Online for appendix
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Molecular targeted therapies have advanced most for 
younger patients with adenocarcinoma, who are mostly 
never-smokers. For patients with advanced NSCLC who 
do not fi t an approved molecular targeted therapy, the 
standard fi rst-line treatment remains platinum-based 
doublet therapy with or without bevacizumab. Note that 
bevacizumab is not applicable to squamous cell histology.
An understanding of the immune landscape of 
tumours, including immune-evasion strategies, has led 
to breakthrough therapeutic advances and made a 
platform for future therapeutic developments.
EGFR-activating mutations
EGFR mutations occur in 10–20% of patients not of east 
Asian descent with NSCLC and in about 40% of Asian 
patients, mostly in adenocarcinoma, younger women 
and girls, and never-smokers.35,71 EGFR TKI-sensitising 
mutations are most frequently seen in exon 19 (deletions) 
or in exon 21 (Leu858Arg). Nine large  phase 3 randomised 
controlled trials (RCTs)36,37,72–74 established the superiority 
of EGFR TKIs as the fi rst-line treatment in EGFR-
mutated NSCLC in terms of progression-free survival, 
objective response rate, and quality of life compared with 
chemotherapy. The impact of EGFR TKIs on survival has 
not been properly assessed in these trials of small sample 
size and high rate of cross-over, although a pooled 
analysis of the LUX-Lung 3 and LUX-Lung 6 trials did 
show an improvement in overall survival with EGFR 
TKIs compared with chemotherapy.75 The LUX-Lung 
studies also provide prospective data on afatinib use in 
uncommon mutations and some diff erences in outcome 
between EGFR mutations.75
Although second-generation TKIs (eg, afatinib) show 
an encouraging improvement in overall survival, they 
also have more toxic eff ects than fi rst-generation TKIs. 
Therefore, which one is preferable as front-line treatment 
remains a question. Results from the LUX-Lung 7 study,38 
a randomised phase 2b study of 319 patients comparing 
afatinib with gefi tinib as fi rst-line therapy, showed a 
statistically signifi cant prolongation of progression-free 
survival (median 11·0 months [95% CI 10·6–12·9] vs 
10·9 months [9·1–11·5]), with HR of 0·73 (p=0·0165) in 
favour of afatinib, and an objective response rate of 70% 
with afatinib versus 56% with gefi tinib (p=0·008). The 
main adverse eff ects of afatinib were diarrhoea (12·5%) 
and rash or acne (9·4%). Drug-related interstitial lung 
disease was not seen in any patients treated with afatinib, 
but was reported in four patients treated with gefi tinib.38
After EGFR TKI treatment, nearly all patients eventually 
had disease progression due to acquired resistance 
(although resistant clones might have been present before 
treatment commenced). Identifi ed resistant mechanisms 
can be categorised as: secondary mutations in EGFR, bypass 
or alternative activations, or histological transformations.36,76,77
The gatekeeper Thr790Met mutation is the most 
frequent secondary EGFR mutation, occurring in 
50–65% of resistant re-biopsies. A third-generation 
irreversible inhibitor (AZD9291, osimertinib) that targets 
both Thr790Met and EGFR TKI-sensitising mutations 
showed an objective response rate of 61% and a median 
progression-free survival of 9·6 months in patients with 
Thr790Met-positive NSCLC who progressed after 
previous TKI therapy.39 The US Food and Drug 
Administration (FDA) and European Medicines Agency 
(EMA) approved osimertinib as a treatment for this 
population. Phase 1–2 studies of CO-1686 (rociletinib), 
HM61713, and others also reported impressive activity.40,78 
For patients whose tumours do not have Thr790Met at 
time of progression after fi rst-line EGFR TKI, platinum-
based chemotherapy seems to be a rational option for 
those not participating in clinical trials.
Treatments after progressive disease develops while 
taking a fi rst-line EGFR TKI should be selected according 
to the patient’s failure pattern.79 For local progression, 
continuation of previous EGFR TKI therapy plus local 
intervention is recommended.80 For slow progression, 
continuation of a fi rst-line TKI with regular monitoring 
will hopefully result in the best outcome.81 For rapid 
systemic progression, switching to a second-line 
treatment based on the genetic profi le of acquired 
resistance is currently being explored, but switching to 
doublet chemotherapy is still the standard of care. In this 
setting, continued administration of gefi tinib combined 
with doublet chemotherapy is not recommended, based 
on results from the IMPRESS trial.82
Studies with the Thr790Met EGFR inhibitors identifi ed 
novel mechanisms of acquired resistance to these 
third-generation TKIs, including the gatekeeper 
EGFR Cys797Ser mutation, HER2 and MET amplifi cation, 
and MAPK activation.83,84
Because of the potential importance of genomic guided 
treatment at the time of progression and the frequent 
diffi  culty of obtaining suffi  cient tissue at the time of 
progression, much eff ort is going into the development of 
blood-based mutation assays. Encouraging results showed 
the detection of Thr790Met mutations in plasma with 
high specifi city (90–100%) and sensitivity (85–90%).85–87
Figure: Frequency of molecular aberrations in driver oncogenes in lung 
adenocarcinomas
EGFR-sensitising (17%)
ALK (7%)
EGFR other (4%)
MET (3%)
>1 mutation (3%)
HER2 (2%)
ROS1 (2%)
BRAF (2%)
RET (2%)
NTRK1 (1%)
PIK3CA (1%)
MEK1 (1%)
Unknown oncogenic 
driver detected (31%)
KRAS (25%)
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Combinations of EGFR TKIs with bevacizumab, 
chemotherapy, and checkpoint inhibition have been 
explored in clinical trials88–90 and might pave a way forward 
in the Thr790Met-negative resistant subgroup.
Brain metastases are an emerging challenge associated 
with poor prognosis. New agents such as AZD3759 and 
epitinib (HMPL-813) that target EGFR mutations have 
been designed for excellent penetration of the central 
nervous system.91
The discovery in 2007 of oncogenic ALK gene 
rearrangements in NSCLC92,93 led to the understanding of 
its implications in the biology and natural history of the 
disease, and subsequently, the development of targeted 
drugs that have dramatically impacted the outcome of 
patients.51,94
ALK rearrangements result from inversions or 
translocations on chromosome 2 that fuse variable 
regions of a partner gene with exon 20 of the ALK gene. 
The most common translocated partner gene in NSCLC 
ALK rearrangement is EML4. Altogether, 27 variants of 
ALK fusion have been described.52
ALK-driven tumours represent 2–7% of NSCLCs,51,53 
and the median age at diagnosis is around 50 years, 
mostly in never-smokers or light smokers with 
adenocarcinomas. Patients are more frequently Asian, 
and 50–60% are men.51
The reference diagnostic assay for detecting ALK 
fusions has been the Vysis LSI ALK Dual Color Break 
Apart FISH Probe (Abbott Molecular, IL, USA).94 
Immunohistochemistry is also approved as a diagnostic 
assay. Of note, ALK fusions are mutually exclusive with 
other oncogenic drivers, such as EGFR, ROS1, and 
KRAS, apart from in exceptional cases.53
Several ALK TKIs, including crizotinib, ceritinib, and 
alectinib, were developed and now constitute the 
backbone of treatment for patients with advanced 
ALK-positive NSCLC.53 Crizotinib targets ALK, ROS1, 
and MET. Patients who received crizotinib had rapid and 
durable responses with a favourable toxic profi le in an 
expanded phase 1 trial and a subsequent phase 2 trial of 
patients mostly previously exposed to chemotherapy.94–96 
Observed progression-free survival was 9·7 in the phase 1 
trial and 8·1 months in the phase 2 trial. Based on these 
results, the FDA and countries including Japan granted 
approval to crizotinib in 2011. Two randomised trials 
have subsequently been completed that were the basis 
for regulatory approval by the EMA and other agencies. 
In the fi rst trial (PROFILE 1007, n=347), crizotinib showed 
longer progression-free survival (7·7 vs 3·0 months) and 
higher objective response rate (65% vs 20%) than 
pemetrexed or docetaxel in patients with advanced 
ALK-positive NSCLC progressing after fi rst-line 
platinum-based chemotherapy.54 The second study 
(PROFILE 1014, n=343) showed the consistent superiority 
of crizotinib in terms of progression-free survival (10·9 vs 
7·0 months) and objective response rate (74% vs 45%) 
over pemetrexed plus platinum chemotherapy in 
untreated patients.55 Neither of these trials showed 
diff erences in overall survival among treatment groups, 
likely due to crossover of patients assigned to the 
chemotherapy regimen.
Status
EGFR
Gefi tinib Approved
Erlotinib Approved
Afatinib Approved
Osimertinib Approved
Necitumumab Approved
ALK
Crizotinib Approved
Alectinib Approved
Ceritinib Approved
Lorlatinib Phase 2
Brigatinib Phase 2
MET
Crizotinib Phase 2
Cabozantinib Phase 2
HER2
Trastuzumab emtansine Phase 2
Afatinib Phase 2
Dacomitinib Phase 2
ROS1
Crizotinib Approved
Cabozantinib Phase 2
Certinib Phase 2
Lorlatinib Phase 2
DS-6051b Phase 1
BRAF
Vemurafenib Phase 2
Dabrafenib Phase 2
RET
Cabozantinib Phase 2
Alectinib Phase 2
Apatinib Phase 2
Vandetanib Phase 2
Ponatinib Phase 2
Lenvatinib Phase 2
NTRK1
Entrectinib Phase 2
LOXO-101 Phase 2
Cabozantinib Phase 2
DS-6501b Phase 1
MEK1
Trametinib Phase 2
Selumetinib Phase 3
Cobimetinib Phase 1
PIK3CA
LY3023414 Phase 2
PQR 309 Phase 1
Table 3: Developmental phases of available drugs against oncogenic proteins 
Seminar
304 www.thelancet.com   Vol 389   January 21, 2017
In patients treated with crizotinib, relapse occurs 
within 1–2 years. CNS is the most frequent, and often 
only, site of relapse or progression regardless of the 
presence of CNS involvement at baseline. This might be 
due to the poor penetrance of crizotinib to the CNS 
(pharmacokinetic resistance), which is the consequence 
of drug effl  ux mediated by the ABCB1 pump.97 Various 
mechanisms of biological acquired resistance to 
crizotinib have been identifi ed.52,98
Treatment strategies resemble those for EGFR-mutant 
tumours. Novel second-generation ALK TKIs, including 
ceritinib and alectinib, among others, with higher 
inhibitory potency to the wild-type fused ALK protein, 
better affi  nity for the secondarily mutated proteins, and 
improved penetrance to the CNS, represent valuable 
treatment alternatives to chemotherapy when crizotinib 
fails. 52,99 Approval was granted to ceritinib by FDA, EMA, 
and many other agencies for the treatment of 
ALK-positive NSCLC after failure on crizotinib (ie, 
disease progression), and alectinib was approved by FDA 
for patients who progress on crizotinib. Both drugs have 
shown durable response in a high proportion of patients, 
and ceritinib showed an objective response rate of 
39–56% and a median progression-free survival of 
5·7–6·9 months.56,100 Phase 3 trials are comparing 
ceritinib with chemotherapy in platinum-exposed and 
chemotherapy-naive patients. Alectinib yielded responses 
in 45–56% of patients after failure of crizotinib treatment, 
with progression-free survival of 8·1–8·9 months in 
phase 1–2 trials.57,101 Alectinib is now being compared 
against chemotherapy in patients with crizotinib failure. 
Importantly, ceritinib and alectinib have shown response 
in patients with identifi able crizotinib-resistant tumour 
mutations at baseline.
Both alectinib and ceritinib have shown impressive 
activity in crizotinib-naive patients in single-arm studies 
(objective response rate 93% for alectinib and 67% for 
ceritinib) with progression-free survival of 19 months for 
alectinib and 27 months for ceritinib.102,103 Alectinib is 
being compared with crizotinib in treatment-naive 
patients in the ALEX phase 3 trial (NCT02075840), and 
one study (J-ALEX)104 reported increased effi  cacy of 
alectinib compared with crizotinib. A number of 
resistance mechanisms for second-generation ALK 
inhibitors, including new secondary mutations and 
alternative signalling routes, result in diff erential 
sensitivity patterns to existing ALK TKIs. Continuous 
assessment of changes in the disease genotype (eg, 
re-biopsy) will be helpful for more precise treatment 
guidance.52
Other ALK inhibitors in development include 
brigatinib, X-396, and PF-06463922.52,58,59
Other actionable aberrations in NSCLC
Chromosomal rearrangement involving the ROS1 gene 
on 6q22 is observed in 1–2% of NSCLC, mostly in 
adenocarcinomas.60,93 Nine fusion protein variants have 
been identifi ed in NSCLC.60,93 A fl uorescence in-situ 
hybridisation (FISH) assay is currently deemed the gold 
standard for ROS1 fusion detection and is used in clinical 
studies.61 Reports support the use of immunohistochemistry 
assays for screening.62 Patients with ROS1-positive NSCLC 
are younger at diagnosis (median about 50 years of age), 
predominantly female, and never or light smokers.60
Crizotinib was assessed as an ROS1 inhibitor in a 
dedicated ROS1-positive NSCLC expansion cohort, and 
was approved by FDA for patients with ROS1-positive 
NSCLC.61 Of 50 patients, mostly pretreated with 
chemotherapy, 72% responded to crizotinib, with a 
median progression-free survival of 19·2 months. 
A European retrospective study of 30 patients reported 
similar results.63 Acquired resistance to crizotinib is 
mediated by secondary mutations of the kinase domain 
(CD74-ROS1 G2032R)64 or by bypass-tract activation, such 
as c-KIT or KRAS.65 Several other ROS1 inhibitors are 
currently being assessed, including ceritinib, cabozantinib, 
entrectinib, and PF06463922.
RET fusion products are detected in 1–2% of NSCLC, 
with greater frequency in never or light smokers bearing 
adenocarcinomas or adenosquamous tumours.105,106 
Multi-targeted TKIs have shown activity against RET 
kinase in preclinical models, such as sunitinib, sorafenib, 
vandetanib, cabozantinib, alectinib, apatinib, lenvatinib, 
and ponatinib, and are now in phase 1 or 2 studies.66
Aberrant overexpression, amplifi cation, and activating 
mutations of the MET receptor tyrosine kinase have been 
observed in specifi c subsets of lung tumours.49 Two 
randomised trials107,108 reported that outcomes for 
pretreated patients not selected for MET genomic 
abnormalities, who received a MET inhibitor (tivantinib 
or onartuzumab) in combination with erlotinib, were the 
same as those treated with the EGFR TKI alone. MET 
gene amplifi cation occurs in about 4% of lung 
adenocarcinomas and 1% of squamous cell lung cancers 
(SCC).49 Evidence suggests that patients with high 
amplifi cation (ie, MET:CEP7 ratio >5) might have a high 
response rate (>35%) to MET inhibitors such as 
crizotinib.70
Paik and colleagues50 reported oncogenic mutations in 
MET exon 14 splice sites that cause exon 14 skipping and 
lead to increased kinase catalytic activity. This mutation 
is seen in 3–4% of lung adenocarcinomas, typically in the 
absence of other drivers. Paik and colleagues previously 
reported response to the MET inhibitors crizotinib and 
cabozantinib in fi ve patients with lung adenocarcinomas 
bearing the MET exon mutation.
HER2 overexpression occurs in 35% of lung cancers, 
and amplifi cation occurs in 10% of lung cancers. The 
data so far do not support routine clinical use of 
HER2-directed therapies in this population beyond 
clinical trials. HER2 mutations are found in about 
2% of NSCLC, mainly in women, never-smokers, 
and adenocarcinoma histology.47 A phase 2 trial48 of 
dacomitinib (objective response rate 12%) supports the 
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effi  cacy of anti-HER2 agents alone or in combination 
with chemotherapy.
BRAF mutations are detected in 3–5% of lung cancers, 
mainly in smokers bearing adenocarcinomas.43,44 The 
Val600Glu mutation is reported in half of patients with 
BRAF-mutated lung adenocarcinomas. A study included 
20 pre-treated patients with BRAF-mutated NSCLC, 18 of 
whom had the Val600Glu mutation.45 The objective 
response rate was 42% and median progression-free 
survival was 7·2 months. A phase 2 study in the same 
patient population using dabrafenib gave consistent 
results.46 A higher activity (objective response rate 63%) 
was documented with dabrafenib combined with the 
MEK1 inhibitor trametinib, as previously seen in 
melanoma.109
KRAS mutations are common aberrations in lung 
cancer and are frequently found in adenocarcinomas 
(25%), particularly in smokers of non-Asian ethnicity.110 
Development of therapeutics to target this phenotype has 
been remarkably frustrating. MEK inhibitors (trametinib 
and selumetinib) have shown signs of activity, more in 
combination with chemotherapy than as monotherapy.41,42
NTRK1 and NTRK2 rearrangements are detected in 
1–2% of NSCLC and several NTRK inhibitors are under 
investigation.69
The Cancer Genome Atlas reported that 96% of 
178 lung SCCs harboured genomic abnormalities, 
including mutations or amplifi cation of FGFR, the PI3K 
pathway, DDR2, EGFR and HER2, and the tumour 
suppressor genes TP53 and P16.111 FGFR amplifi cation 
was seen in about 5–22% of SCC, and DDR2 mutations 
were seen in about 4% of SCC.112,113 None of these 
alterations defi nes a subset of SCC whose patients are 
known to benefi t from specifi c therapies, although a 
number of agents targeting these dysregulated pathways 
are being assessed preclinically and in early clinical trials.
In SCLC, there is an almost universal inactivation of 
TP53 and RB1, sometimes by complex genomic 
rearrangements.114 About a quarter of cases show 
inactivating mutations in the NOTCH gene family.
Unlike other types of lung cancer, SCLC has had no 
breakthrough agents in the last 25 years, with only one 
agent approved, topotecan (for second-line treatment). 
SCLC is usually chemo-sensitive but in most cases 
resistance rapidly develops.115 Thus, essentially all patients 
of any stage receive a doublet combination of etoposide 
(or irinotecan in Japan) with cisplatin or carboplatin.
Limited stage disease (ie, tumours that are located in 
the ipsilateral hemithorax and treatable with a single 
radiation fi eld) occurs in only one-third of patients with 
SCLC and is potentially curable. Combined-modality 
therapy (chemotherapy and radiotherapy) has long been 
the mainstay of therapy for this condition, but more 
recent data suggest a role for surgery in early stage 
disease. Prophylactic cranial irradiation seems to 
improve outcomes in patients who have responded to 
initial therapy.116
Anti-VEGF inhibitors have been used in combination 
with chemotherapy for the treatment of lung cancer on 
the basis of modestly improved outcomes. For safety 
reasons, these agents have been restricted to patients with 
adenocarcinoma with a low risk of haemoptysis. A novel 
monoclonal antibody directed at the VEGF receptor, 
ramucirumab, has been approved by the FDA and EMA 
for use in combination with docetaxel in the second-line 
treatment of squamous and non-squamous NSCLC.117 
Another antiangiogenic agent,118 the multikinase inhibitor 
nintedanib, resulted in similar survival benefi ts when 
combined with docetaxel, but only in patients with 
adenocarcinoma. Nintedanib is EMA approved but not 
FDA approved. 
Necitumumab is another monoclonal antibody against 
EGFR, which was shown to improve survival in untreated 
patients with advanced SCC when combined with 
cisplatin and gemcitabine (HR 0·84, 95% CI 0·74–0·96; 
p=0·01).118 The drug was approved by the FDA but 
restricted to those tumours with positive EGFR 
expression by the EMA.119
Immunotherapy
Lung cancer initiation and progression depends not only 
on the evolving genomics and molecular properties of 
cancer cells but also on their interaction with the tumour 
environment, specifi cally with the immune system.120 
Therapeutic approaches that modulate the immune 
system in patients with lung cancer have traditionally 
focused on vaccines, and have generally been ineff ective, 
probably due to insuffi  cient or inadequate immune 
activation (TG4010, which has shown some positive 
results, remains under investigation).120–122 Immunotherapy 
approaches have focused on a series of ligands and 
receptors that inhibit or stimulate the immunological 
synapse.123
Inhibitory checkpoint molecules generated upon T-cell 
activation, such as those that regulate the immunological 
synapse between T cells and dendritic cells in lymph 
nodes (CTLA-4–B7.1), thereby suppressing T-cell activation, 
or between T cells and tumour cells in the tumour bed 
(programmed death-1 [PD-1]–programmed death-ligand 
[PD-L]1, PD-L2), hampering immune rejection or the 
eff ector phase, are currently the most relevant targets for 
immunotherapy. Antibody-directed therapies against 
these checkpoints have shown remarkable early success 
in many malignancies and already have a major role in the 
management of advanced lung cancer and other tumours 
(table 4).124
Several monoclonal antibodies directed to the PD-1 
receptor (nivolumab, pembrolizumab) or its ligand PD-L1 
(atezolizumab, durvalumab, avelumab) have reached the 
clinic, and others are in preclinical development. Early 
clinical trials with these agents have shown rapid and 
durable responses in about 14–20% of pre-treated patients 
with advanced NSCLC.128–134 Importantly, even though 
progression-free survival fi gures are not impressive 
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(median 2–4 months; progression-free survival at 1 year 
20%), survival outcomes are remarkable. In the 27-month 
follow-up of a cohort of 129 patients with NSCLC treated 
with nivolumab,131 2-year survival was 24% in the overall 
population and 42% in the subset of patients treated at 
the dose selected for further development (3 mg/kg every 
2 weeks); 3-year survival was 18% in the overall population 
and 27% in the development dose subset of patients. 
Clinical effi  cacy appeared independent of histology, but 
in most of the trials greater benefi t was observed in 
smokers and in patients with PD-L1-positive expression. 
The toxic profi le of these agents is quite favourable, with 
about 10% of patients developing severe (grades III–IV) 
adverse events.125–130,132–134 The most frequent adverse eff ects 
observed were asthenia, fatigue, loss of appetite, nausea, 
and diarrhoea. Less than 10% of patients developed 
immune-related side-eff ects including rash, colitis, 
transaminitis, pneumonitis, and endocrinopathies.
Clinical effi  cacy and safety of the anti-PD-1 or anti-PD-L1 
agents is supported by four randomised studies.125–128 Two 
trials compared nivolumab to docetaxel in patients 
who progressed to platinum-based chemotherapy, in 
SCC (CheckMate 017 trial)125 and non-SCC NSCLC 
(CheckMate 057 trial).126 In patients with SCC, nivolumab 
resulted in improved survival (median 9·2 vs 6·0 months, 
HR 0·59; p<0·001), progression-free survival (3·5 vs 2·8, 
0·62; p<0·001), and response rate (20% vs 9%, p<0·008) 
over docetaxel.130 Nivolumab benefi ts were largely 
independent of clinical and tumour characteristics, 
including PD-L1 expression. In the non-SCC trial, 
nivolumab improved survival (median 12·2 vs 9·4 months, 
HR 0·73) and response rate (p<0·02) but not progression-
free survival in the overall population.126 Treatment eff ect 
was seen in all patient subgroups except for never-smokers 
and those with wild-type EGFR tumours. In non-SCC, 
PD-L1 expression emerged as a substantial determinant of 
nivolumab benefi t. Nivolumab has obtained regulatory 
approval in the USA (SCC and non-SCC) and the EU 
(SCC) for the treatment of advanced disease in patients 
who have progressed on fi rst-line chemotherapy.
Irrespective of the use of a diff erent clone and assay for 
PD-L1 determination, along with diff erent criteria for 
positivity (ie, staining of immune cells within the tumour 
was taken into account), the benefi t from the checkpoint 
inhibitor was mostly restricted to the PD-L1-positive 
tumour population. A randomised phase 3 trial of 
pembrolizumab versus docetaxel in patients harbouring 
PD-L1-positive tumours (>1% of cells) favoured the 
anti-PD-1 treatment, and the magnitude of the survival 
benefi t was related to PD-L1 expression (HR of 0·53 if 
CheckMate 017 
phase 3¹²⁵
CheckMate 057 
phase 3¹²⁶
KEYNOTE-010 phase 3¹²⁷ POPLAR phase 2¹²⁸ Durvalumab 
phase 1b¹²⁹
Avelumab 
phase 1b¹³⁰
Nivolumab Docetaxel Nivolumab Docetaxel Pembrolizumab 
2 mg/kg
Pembrolizumab 
10 mg/kg
Docetaxel Atezolizumab Docetaxel Durvalumab Avelumab
Patients (n) 135 137 292 290 345 346 343 144 143 198 184
Response rate (%)
All patients 20 9 19 12 18 19 9 15 15 16 14
PD-L1 positive 21 8 36 13 30 29 8 38 13 27 16
PD-L1 negative 15 12 10 14 NA NA NA 8 10 5 10
Median progression-free survival (months)
All patients 3·5 2·8 2·3 4·2 3·9 4·0 4·0 2·7 3·0 NA 2·9
PD-L1 positive 4·8 3·1 5·0 3·8 5·0 5·2 4·1 2·8 3·0 NA 3·0
PD-L1 negative 4·2 2·9 2·1 4·2 NA NA NA 1·7 4·1 NA 1·4
Median overall survival (months)
All patients 9·2 6·0 12·2 9.4 10·4 12·7 8·5 12·6 9·7 NA 8·9
PD-L1 positive 10 6·4 19·4 8·1 14·9 17·3 8·2 15·5 9·2 NA 8·4
PD-L1 negative 8·5 6·1 9·8 10·1 NA NA NA 9·7 9·7 NA 4·6
Histology SCC SCC Non-SCC Non-SCC All comers All comers All comers All comers All comers All comers All comers
Setting Second line Second 
line
Second line Second 
line
Second line Second line Second line Second line Second line Pre-treated Pre-treated
PD-L1 expression
Positive ≥5% ≥5% ≥5% ≥5% Highly positive 
≥50%; positive 
≥1%
Highly positive 
≥50%; positive 
≥1%
Highly 
positive 
≥50%; 
positive 
≥1%
Tumour cell 1–3 or tumour-
infi ltrating immune cells 1–3
≥25% ≥1%
Negative <5% <5% <5% <5% <1% (not 
included)
<1% (not 
included)
<1% (not 
included)
Tumour cell 0 and tumour-
infi ltrating immune cells 0
<25% <1%
Percentages rounded. PD-1=programmed death-1. PD-L1=programmed death ligand-1. SCC=squamous cell cancer. NA=not available.
Table 4: Trials of anti-PD-1/PD-L1 inhibitors in patients with advanced NSCLC who were pre-treated with chemotherapy
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PD-L1 >50%; HR of 0·76 if PD-L1 expression 1–49%).127 
Pembrolizumab has been FDA approved for second or 
further lines of treatment if tumour expression of PD-L1 
is encountered in ≥50% of cells, independent of histology. 
Although results from comparative studies of immune 
therapy and chemotherapy as fi rst-line treatment for 
advanced NSCLC are still pending, Merck announced 
that a large study135 met its endpoints of progression-free 
survival and overall survival benefi t for pembrolizumab 
versus chemotherapy in patients with PD-L1-expressing 
tumours (≥50%).
Atezolizumab showed benefi t over docetaxel in 
a randomised phase 2 trial including all NSCLC 
histologies.128
Overall data suggest PD-1 inhibitors are a preferred 
second-line treatment over standard chemotherapy in 
SCC and at least in PD-L1-positive, non-SCC of the lung. 
However, a remaining question is the optimal defi nition 
of PD-L1 expression in terms of prediction of benefi t. Not 
all patients with PD-L1-positive NSCLC benefi t from 
these agents, and some PD-L1-low-expressing or 
PD-L1-negative tumours do. All the PD-L1 assays diff er in 
terms of antibodies used, assessment methods, targeting 
cells, and cutoff s for positive and negative results.136 To 
elucidate similarities and diff erences between the 
diff erent PD-L1 assays, comparative studies are ongoing 
on a standardised set of NSCLC tumours.136
In previously untreated patients, results of early trials 
have reported encouraging results with anti-PD-1 or anti-
PD-L1 inhibitors, including 1-year survival exceeding 70% 
in PD-L1-positive tumours.117,137 Several trials are currently 
comparing these agents with platinum combination 
regimens as front-line therapy. Trials are also ongoing in 
earlier disease settings (stage III, post-surgery), and early 
data are encouraging in other thoracic malignancies, such 
as small-cell lung cancer (SCLC) and mesothelioma.138,139
Maintenance therapy for patients with advanced NSCLC
The optimal duration of treatment for patients with 
advanced NSCLC has been investigated in several 
studies. The administration of 4–6 cycles of combination 
chemotherapy followed by observation has become the 
standard of care for the fi rst-line treatment of advanced 
NSCLC.140,141
To date, both switch therapy strategies (in which a 
diff erent therapy than the fi rst-line therapy is used) with 
pemetrexed142 and erlotinib,143 or continuation 
maintenance with pemetrexed144 improved outcomes, 
including overall survival and progression-free survival 
(table 5). Several meta-analyses have supported the 
impact of maintenance treatment approaches on effi  cacy 
outcomes and toxicity.150,151 Overall, these studies 
substantiated a highly signifi cant impact from 
maintenance therapy on progression-free survival 
(HR 0·53–0·67) and, to a lesser extent, on overall survival 
(0·85–0·88), with some increases in clinically relevant 
toxicities but maintaining the quality of life of treated 
patients. Switch maintenance strategies are not used 
frequently in practice compared with continuation 
maintenance, as physicians and patients most often 
prefer to extract the maximum benefi t from a given 
therapy before switching to an alternative treatment.
Maintenance therapy with an EGFR inhibitor is 
indicated for patients with activating EGFR TKI-
sensitising tumour mutations who for any reason (eg, 
delayed information on EGFR mutation profi ling) are 
given fi rst-line chemotherapy.152
Several factors infl uence the decision to implement 
maintenance therapy. These included tumour histology 
(pemetrexed being indicated only in patients with non-
squamous NSCLC), genomics, response to induction, 
patient health status (performance status ≥2 precludes 
benefi t from this approach) and, most importantly, 
patient choice.141 From the patient’s perspective, an 
overall survival benefi t of at least several months 
(eg, 3 months in the Paramount trial)144 or better symptom 
control is expected, to balance mild-to-moderate side-
eff ects.
Conclusion
Although lung cancer has long been a disease 
characterised by late-stage diagnosis and no progress in 
treatment options, the last decade has yielded 
encouraging results with lung cancer screening in 
high-risk populations and substantial progress with 
systemic therapies for molecular subgroups of patients 
with advanced disease. Further progress is expected for 
these patient subgroups through the development of 
next-generation drugs that have more-specifi c target 
eff ects, and target of specifi c resistant mutations, creating 
a chronic therapeutic pathway.
Furthermore, new molecular targets are continuously 
detected, prompting the development of new therapies. 
For many subgroups of patients with NSCLC, future 
combination therapy (using targeted therapies or 
immunotherapies) could be the ultimate curative option.
n Maintenance 
drug
Progression-free 
survival HR 
(95% CI)
Overall survival HR 
(95% CI)
Switch maintenance trials
Westeel et al145 181 Vinorelbine 0·77 (0·56–1·07) 1·08 (0·79–1·47)
Fidias et al146 309 Docetaxel 0·71 (0·55–0·92) 0·84 (0·65–1·08)
Cappuzzo et al143 889 Erlotinib 0·71 (0·62–0·82) 0·81 (0·70–0·95)
Ciuleanu et al142 663 Pemetrexed 0·60 (0·49–0·73) 0·79 (0·65–0·95)
Continuation maintenance trials
Paz-Ares et al144 539 Pemetrexed 0·62 (0·49–0·79) 0·78 (0·64–0·96)
Brodowicz et al147 206 Gemcitabine 0·69 (0·56–0·86) 0·84 (0·52–1·30)
Belani et al148 255 Gemcitabine 1·09 (0·81–1·45) 0·97 (0·72–1·30)
Perol et al149 309 Gemcitabine 0·56 (0·44–0·72) 0·89 (0·67–1·15)
HR=hazard ratio.
Table 5: Effi  cacy of maintenance chemotherapy in clinical trials in advanced non-small-cell lung cancer
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